sts66, "Settlements" like the one Teva did are the norm. Usually, the generics do not even want to go into a market until it is mature... why sell generic Vascepa when the market is under $500 million when in 10 years the market should be 10 or even 20 times that amount.
My pharma lit guy says that when a drug is approved for multiple indications, there is a procedure (called a Section 8 carve-out) that allows a generic to seek approval for some, but not all, of the indications.
News 
Market Data 
Discover 
